HIRALAL MAHESHWARI
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
- Where
- CRYSTAL LAKE, IL
- NPI
- 1740238757
- Received
- $88,008 in 1,044 records, 2019 to 2024 ($86,036 general, $1,972 research)
- As principal investigator
- $556,186 of research payments to others in 89 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 211 | $4,367 |
| 2023 | Research payment | 1 | $530 |
| 2022 | General payment | 197 | $23,134 |
| 2021 | General payment | 226 | $20,402 |
| 2020 | General payment | 178 | $15,729 |
| 2019 | General payment | 216 | $22,402 |
| 2019 | Research payment | 15 | $1,442 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 33 | $62,633 |
| Food and Beverage | 968 | $20,656 |
| Travel and Lodging | 22 | $2,700 |
| Research payment | 16 | $1,972 |
| Education | 5 | $46 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-24 | Abbott Laboratories | $5 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-12-21 | Dexcom, Inc. | $14 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-12-15 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2023 | |
| 2023-12-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-12-08 | Mannkind Corporation | $10 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-12-07 | Dexcom, Inc. | $45 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-12-05 | Halozyme Inc | $17 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2023 | |
| 2023-12-04 | KYOWA KIRIN, INC. | $16 | Food and Beverage | In-kind items and services | Crysvita Drug, fibroblast growth factor 23 (FGF23) blocking antibody. | 2023 | |
| 2023-11-30 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-11-30 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-11-30 | Abbott Laboratories | $7 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-11-27 | IBSA Pharma Inc. | $15 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-11-22 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-11-20 | Tandem Diabetes Care, Inc. | $16 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-11-16 | Amphastar Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | BAQSIMI Drug, Diabetes | 2023 | |
| 2023-11-13 | Lexicon Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | Inpefa Drug, Inhibitor of SGLT2 and SGLT1 | 2023 | |
| 2023-11-09 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-11-09 | Lilly USA, LLC | $1 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-11-08 | Lilly USA, LLC | $24 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-11-02 | Dexcom, Inc. | $44 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-10-31 | Mannkind Corporation | $9 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-10-30 | IBSA Pharma Inc. | $15 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-10-28 | Lilly USA, LLC | $9 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-10-27 | Abbott Laboratories | $21 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-10-26 | Lilly USA, LLC | $33 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-10-24 | Amneal Pharmaceuticals LLC | $15 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-10-24 | Dexcom, Inc. | $6 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-10-23 | RECORDATI_RARE_DISEASES_INC. | $24 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2023 | |
| 2023-10-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-10-18 | Halozyme Inc | $22 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2023 | |
| 2023-10-14 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-10-12 | Abbott Laboratories | $8 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-10-12 | Lilly USA, LLC | $5 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-10-11 | Insulet Corporation | $24 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-10-10 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-10-10 | Lilly USA, LLC | $5 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-10-10 | Lilly USA, LLC | $0 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-10-09 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2023 | |
| 2023-10-08 | Mannkind Corporation | $9 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-10-05 | Dexcom, Inc. | $44 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-10-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-09-29 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-09-26 | IBSA Pharma Inc. | $15 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-09-14 | Lilly USA, LLC | $26 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-09-12 | KYOWA KIRIN, INC. | $17 | Food and Beverage | In-kind items and services | Crysvita Drug, fibroblast growth factor 23 (FGF23) blocking antibody. | 2023 | |
| 2023-09-07 | Dexcom, Inc. | $49 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-09-07 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-09-05 | Tandem Diabetes Care, Inc. | $21 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-09-05 | Amneal Pharmaceuticals LLC | $14 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-08-31 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-08-29 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-08-29 | Mannkind Corporation | $9 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-08-29 | Lilly USA, LLC | $2 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-08-28 | Lilly USA, LLC | $4 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-08-25 | RECORDATI_RARE_DISEASES_INC. | $18 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2023 | |
| 2023-08-25 | Mannkind Corporation | $10 | Education | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-08-23 | Abbott Laboratories | $6 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-08-22 | Amneal Pharmaceuticals LLC | $24 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-08-22 | Lilly USA, LLC | $8 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-08-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-21 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | 2023 | |
| 2023-08-18 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-08-15 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-08-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-08-10 | Corcept Therapeutics | $22 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-08-08 | Mannkind Corporation | $19 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-08-07 | Abbott Laboratories | $61 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-08-07 | Halozyme Inc | $18 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2023 | |
| 2023-08-04 | SANOFI-AVENTIS U.S. LLC | $24 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-08-03 | Dexcom, Inc. | $39 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-08-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-07-31 | IBSA Pharma Inc. | $15 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-07-27 | Lilly USA, LLC | $29 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-07-26 | Mannkind Corporation | $7 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-07-25 | Amneal Pharmaceuticals LLC | $14 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-07-19 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-07-19 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2023 | |
| 2023-07-18 | Lilly USA, LLC | $1 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-07-17 | Xeris Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2023 | |
| 2023-07-14 | RECORDATI_RARE_DISEASES_INC. | $12 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2023 | |
| 2023-07-13 | Corcept Therapeutics | $16 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-07-13 | Lilly USA, LLC | $5 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-07-12 | Mannkind Corporation | $11 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-07-10 | Dexcom, Inc. | $44 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-05 | Lilly USA, LLC | $8 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-05 | Lilly USA, LLC | $1 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-01 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-06-29 | Amneal Pharmaceuticals LLC | $12 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-06-26 | Azurity Pharmaceuticals, Inc. | $22 | Food and Beverage | Cash or cash equivalent | Adthyza Drug, Endocrinology | 2023 | |
| 2023-06-22 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2023 | |
| 2023-06-21 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-06-20 | Mannkind Corporation | $11 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-06-16 | Dexcom, Inc. | $174 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-06-15 | Corcept Therapeutics | $27 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-06-14 | Abbott Laboratories | $23 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-06-14 | Abbott Laboratories | $5 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-06-14 | Abbott Laboratories | $1 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-06-12 | Lilly USA, LLC | $29 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-06-12 | Lilly USA, LLC | $0 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-06-09 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-06-08 | RECORDATI_RARE_DISEASES_INC. | $18 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2023 | |
| 2023-06-06 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-06-06 | Mannkind Corporation | $10 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-06-06 | Mannkind Corporation | $0 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-06-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-06-01 | Dexcom, Inc. | $39 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-06-01 | Corcept Therapeutics | $15 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-06-01 | Dexcom, Inc. | $4 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-05-30 | Amneal Pharmaceuticals LLC | $10 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-05-30 | SANOFI-AVENTIS U.S. LLC | $6 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-05-25 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-05-25 | Corcept Therapeutics | $6 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-05-25 | Lilly USA, LLC | $1 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-05-24 | Lilly USA, LLC | $113 | Food and Beverage | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-05-23 | IBSA Pharma Inc. | $15 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-05-23 | Tandem Diabetes Care, Inc. | $14 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-05-18 | Mannkind Corporation | $11 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-05-18 | Mannkind Corporation | $0 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-05-17 | Dexcom, Inc. | $79 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-05-17 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-05-17 | Abbott Laboratories | $6 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-05-16 | Bayer Healthcare Pharmaceuticals Inc. | $31 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-05-11 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | BAQSIMI Drug, Diabetes | 2023 | |
| 2023-05-09 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-05-09 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-05-09 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-05-08 | SANOFI-AVENTIS U.S. LLC | $20 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-05-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-05-04 | Dexcom, Inc. | $36 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-05-03 | Embecta Corp. | $22 | Food and Beverage | In-kind items and services | BD Nano 2nd Gen Pen Needle Device, Diabetes Care | 2023 | |
| 2023-05-02 | SANOFI-AVENTIS U.S. LLC | $9 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-04-30 | Eli Lilly and Company | $530 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-04-24 | Antares Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | NOCDURNA Drug, NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | 2023 | |
| 2023-04-20 | Corcept Therapeutics | $21 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-04-18 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2023 | |
| 2023-04-17 | Amneal Pharmaceuticals LLC | $13 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-04-17 | Antares Pharma, Inc. | $10 | Food and Beverage | In-kind items and services | NOCDURNA Drug, NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | 2023 | |
| 2023-04-13 | Dexcom, Inc. | $41 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-04-13 | Lilly USA, LLC | $9 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-04-12 | Mannkind Corporation | $84 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-04-12 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-04-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-04-10 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | BAQSIMI Drug, Diabetes | 2023 | |
| 2023-04-07 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | STEGLATRO Drug, ENDOCRINOLOGY | 2023 | |
| 2023-04-07 | Mannkind Corporation | $10 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-04-06 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-04-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-04-03 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-03-30 | Azurity Pharmaceuticals, Inc. | $16 | Food and Beverage | Cash or cash equivalent | Adthyza Drug, Endocrinology | 2023 | |
| 2023-03-25 | Alexion Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | STRENSIQ Biological, Rare Disease | 2023 | |
| 2023-03-23 | IBSA Pharma Inc. | $21 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-03-23 | SANOFI-AVENTIS U.S. LLC | $7 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-03-23 | Dexcom, Inc. | $5 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-03-21 | Abbott Laboratories | $84 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-03-21 | Corcept Therapeutics | $25 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-03-21 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2023 | |
| 2023-03-21 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-03-21 | Abbott Laboratories | $11 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-03-21 | Abbott Laboratories | $4 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-03-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-03-10 | Mannkind Corporation | $10 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-03-10 | Corcept Therapeutics | $7 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-03-10 | Mannkind Corporation | $1 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-03-09 | Dexcom, Inc. | $39 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-03-07 | SANOFI-AVENTIS U.S. LLC | $22 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-03-07 | Xeris Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2023 | |
| 2023-03-06 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-03-02 | RECORDATI_RARE_DISEASES_INC. | $18 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2023 | |
| 2023-02-28 | Antares Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | NOCDURNA Drug, NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | 2023 | |
| 2023-02-28 | Lilly USA, LLC | $5 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-02-27 | Amneal Pharmaceuticals LLC | $15 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-02-23 | Antares Pharma, Inc. | $87 | Food and Beverage | In-kind items and services | TLANDO Drug, TESTOSTERONE REPLACEMENT THERAPY | 2023 | |
| 2023-02-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | TRADJENTA Drug, DIABETES | 2023 | |
| 2023-02-22 | Antares Pharma, Inc. | $9 | Food and Beverage | In-kind items and services | NOCDURNA Drug, NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | 2023 | |
| 2023-02-21 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2023 | |
| 2023-02-21 | Corcept Therapeutics | $23 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-02-18 | Mannkind Corporation | $8 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-02-17 | Mannkind Corporation | $6 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2023 | |
| 2023-02-16 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-02-14 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | BAQSIMI Drug, Diabetes | 2023 | |
| 2023-02-13 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2023 | |
| 2023-02-10 | Lilly USA, LLC | $24 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-02-07 | SANOFI-AVENTIS U.S. LLC | $26 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-02-04 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-02-02 | Corcept Therapeutics | $82 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-02-02 | Dexcom, Inc. | $39 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-01-31 | Amneal Pharmaceuticals LLC | $21 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2023 | |
| 2023-01-30 | Abbott Laboratories | $7 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-01-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-01-26 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-01-26 | Lilly USA, LLC | $7 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-01-24 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2023 | |
| 2023-01-24 | Corcept Therapeutics | $22 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-01-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10 | Food and Beverage | In-kind items and services | TRADJENTA Drug, DIABETES | 2023 | |
| 2023-01-24 | Abbott Laboratories | $5 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-01-23 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 |
The latest 200 records of 1,044.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2024-01-31 | Eli Lilly and Company | MIDWEST CRC INC | $379 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2023-12-19 | Novartis Pharmaceuticals Corporation | MIDWEST CRC INC | $18,601 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-08-28 | Novartis Pharmaceuticals Corporation | MIDWEST ENDOCRINOLOGY ASSOCIATES RESEARCH | $322 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-05-25 | Novartis Pharmaceuticals Corporation | MIDWEST ENDOCRINOLOGY ASSOCIATES RESEARCH | $19,882 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-04-13 | Eli Lilly and Company | MIDWEST CRC INC | $1,404 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-01-12 | ABBVIE INC. | MIDWEST CRC INC | $453 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2023 |
| 2022-12-15 | ABBVIE INC. | MIDWEST CRC INC | $2,265 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-11-09 | ABBVIE INC. | MIDWEST CRC INC | $6,700 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-09-08 | ABBVIE INC. | MIDWEST CRC INC | $1,081 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-08-10 | ABBVIE INC. | MIDWEST CRC INC | $27,725 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-07-07 | ABBVIE INC. | MIDWEST CRC INC | $589 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-05-05 | ABBVIE INC. | MIDWEST CRC INC | $35,332 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-04-07 | ABBVIE INC. | MIDWEST CRC INC | $221 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-03-08 | ABBVIE INC. | MIDWEST CRC INC | $6,546 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2022-02-03 | ABBVIE INC. | MIDWEST CRC INC | $7,016 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascula | 2022 |
| 2021-11-09 | ABBVIE INC. | MIDWEST CRC INC | $6,871 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2021-10-07 | ABBVIE INC. | MIDWEST CRC INC | $110 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2021-07-29 | ABBVIE INC. | MIDWEST CRC INC | $1,595 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2021-07-08 | ABBVIE INC. | MIDWEST CRC INC | $63 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2021-05-27 | ABBVIE INC. | MIDWEST CRC INC | $152 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2021-04-29 | ABBVIE INC. | MIDWEST CRC INC | $5,243 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2021-03-02 | ABBVIE INC. | MIDWEST CRC INC | $1,048 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2021-02-02 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $27,300 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2021 |
| 2021-01-28 | ABBVIE INC. | MIDWEST CRC INC | $2,719 | Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (T | 2021 |
| 2020-12-30 | ABBVIE INC. | MIDWEST CRC INC | $12,958 | M16-100 | 2020 |
| 2020-12-01 | ABBVIE INC. | MIDWEST CRC INC | $15,141 | M16-100 | 2020 |
| 2020-10-29 | ABBVIE INC. | MIDWEST CRC INC | $19,448 | M16-100 | 2020 |
| 2020-09-30 | ABBVIE INC. | MIDWEST CRC INC | $11,545 | M16-100 | 2020 |
| 2020-09-08 | SANOFI US SERVICES INC. | Midwest Crc Incorporation | $280 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2020 |
| 2020-09-02 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $6,755 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-08-28 | ABBVIE INC. | MIDWEST CRC INC | $2,525 | M16-100 | 2020 |
| 2020-08-13 | Lexicon Pharmaceuticals, Inc. | MIDWEST CRC INC | $14,741 | EFC-14875 | 2020 |
| 2020-07-30 | ABBVIE INC. | MIDWEST CRC INC | $982 | M16-100 | 2020 |
| 2020-07-20 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $17,960 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2020 |
| 2020-06-30 | ABBVIE INC. | MIDWEST CRC INC | $39 | M16-100 | 2020 |
| 2020-06-15 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,990 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-05-28 | ABBVIE INC. | MIDWEST CRC INC | $166 | M16-100 | 2020 |
| 2020-04-30 | ABBVIE INC. | MIDWEST CRC INC | $1,529 | M16-100 | 2020 |
| 2020-04-06 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $13,201 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2020 |
| 2020-03-30 | ABBVIE INC. | MIDWEST CRC INC | $2,032 | M16-100 | 2020 |
| 2020-03-10 | ABBVIE INC. | MIDWEST CRC INC | $1,151 | M16-100 | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $3,515 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-02-18 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,045 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-02-18 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $994 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2020 |
| 2020-02-04 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $14,654 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2020 |
| 2020-01-30 | ABBVIE INC. | MIDWEST CRC INC | $5,653 | M16-100 | 2020 |
| 2020-01-27 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,889 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2020 |
| 2020-01-13 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $6,498 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2020 |
| 2019-12-11 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $1,487 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-12-11 | ABBVIE INC. | MIDWEST CRC INC | $1,098 | M16-100 | 2019 |
| 2019-11-27 | ABBVIE INC. | MIDWEST CRC INC | $2,208 | M16-100 | 2019 |
| 2019-11-25 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,050 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-11-12 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,200 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-12 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $1,150 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-12 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,864 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-11-04 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $850 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-11-04 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $1,920 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-10-30 | ABBVIE INC. | MIDWEST CRC INC | $2,402 | M16-100 | 2019 |
| 2019-10-21 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,371 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2019 |
| 2019-10-21 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,629 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-10-21 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,912 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-10-07 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $4,606 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-09-30 | ABBVIE INC. | MIDWEST CRC INC | $10,580 | M16-100 | 2019 |
| 2019-09-23 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $4,001 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-09-09 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $1,019 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-09-03 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,772 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2019 |
| 2019-08-29 | ABBVIE INC. | MIDWEST CRC INC | $24,907 | M16-100 | 2019 |
| 2019-08-07 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,043 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-07-30 | ABBVIE INC. | MIDWEST CRC INC | $1,945 | M16-100 | 2019 |
| 2019-07-29 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,729 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2019 |
| 2019-07-29 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,052 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-07-25 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,400 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-07-02 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $1,250 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2019 |
| 2019-06-20 | ABBVIE INC. | MIDWEST CRC INC | $1,856 | M16-100 | 2019 |
| 2019-06-10 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $1,492 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2019 |
| 2019-06-10 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,622 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-06-03 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $16,680 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-05-16 | ABBVIE INC. | MIDWEST CRC INC | $10,839 | M16-100 | 2019 |
| 2019-04-22 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $1,237 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2019 |
| 2019-04-22 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,110 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-04-16 | ABBVIE INC. | MIDWEST CRC INC | $12,235 | M16-100 | 2019 |
| 2019-04-15 | SANOFI US SERVICES INC. | MIDWEST ENDOCRINOLOGY LLC | $11,405 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-04-01 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $2,454 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-03-25 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $5,000 | Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR | 2019 |
| 2019-03-22 | ABBVIE INC. | MIDWEST CRC INC | $6,657 | M16-100 | 2019 |
| 2019-02-18 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $6,177 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-01-28 | SANOFI US SERVICES INC. | MIDWEST CRC INC | $12,975 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-01-18 | ABBVIE INC. | MIDWEST CRC INC | $11,139 | M16-100 | 2019 |
| 2019-01-15 | AstraZeneca Pharmaceuticals LP | MIDWEST CRC INC | $7,533 | A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice dai | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Crystal Lake, IL, county McHenry County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Crystal Lake, IL | County McHenry County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 40,579 | 312,591 | 12,694,798 |
| Population, 2020 census P1 | 40,269 | 310,229 | 12,812,508 |
| Median age B01002 | 39.3 | 40.7 | 39.0 |
| Under 18 B01001 | 23.4% | 22.7% | 21.8% |
| 65 and over B01001 | 14.9% | 16.5% | 17.0% |
| Households B11001 | 14,806 | 117,594 | 5,036,449 |
| Foreign born B05002 | 10.4% | 9.9% | 14.7% |
| Median household income B19013 | $108,418 | $104,802 | $83,390 |
| Median family income B19113 | $125,833 | $124,289 | $106,018 |
| Per capita income B19301 | $46,472 | $49,388 | $46,406 |
| Poverty rate B17001 | 6.8% | 6.2% | 11.8% |
| Unemployment rate B23025 | 4.2% | 4.7% | 5.8% |
| Civilian labor force B23025 | 23,231 | 174,633 | 6,652,134 |
| Mean commute (minutes) B08013 | 29.3 | 30.1 | 27.8 |
| Bachelor's degree or higher B15003 | 42.0% | 35.2% | 37.8% |
| Housing units B25001 | 15,256 | 121,329 | 5,457,452 |
| Owner-occupied B25003 | 77.6% | 82.7% | 67.1% |
| Renters B25003 | 22.4% | 17.3% | 32.9% |
| Median home value B25077 | $311,400 | $308,100 | $263,300 |
| Median gross rent B25064 | $1,468 | $1,401 | $1,274 |
| White, not Hispanic B03002 | 78.3% | 76.1% | 58.1% |
| Black B03002 | 0.6% | 1.4% | 13.3% |
| Hispanic or Latino B03002 | 13.8% | 16.1% | 18.8% |
| Asian B03002 | 3.7% | 3.0% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Crystal Lake, IL.
Comments